ETR by baseline tumor burden in phase 1 and 2 of the GAUGUIN study. *In phase 1 of GAUGUIN, 4 different doses of obinutuzumab were evaluated. In phase 2, all patients received obinutuzumab 1000/1000 mg. The size of the bar below the x-axis reflects the dose received by the patient.